• Facebook
  • Twitter
  • LinkedIn

©2017 BY EPISCI

Scientist in the Lab

IN THE PIPELINE

epiSCI is developing proprietary in vitro tumor models for 200 carcinoma indications, including rare and underserved cancers, one carcinoma at a time.

Leveraging our biomarker discovery, and our accumulated knowledge database, our pipeline includes targeted nanodelivery of oncology drugs. 

Our first drugs in preclinical development TSK-001, and TSK-002 for oral carcinoma and prostate cancer respectively are activatable cell penetrating peptides tagged with a warhead and directed against the cancer stem cells that have undergone epithelial to mesenchymal transition.

Targeted delivery & pathways of interest
 
new7.png

EPISCI: EPITHELIAL STEM CELL INNOVATION

The right in vitro platform to develop the right drug, delivered to the right cells,

in the right patient.

Clinical Trial on a Dish (TM)

​

Get In Touch
  • Home

  • The epiSCI difference

  • biomarkers

  • In the pipeline

  • Resources

  • Research

  • Contact

  • Blog

  • More